Glypican-1 as a novel immunotherapeutic target in prostate cancer.

被引：4
|
作者：
Zaslavsky, Alexander
Adams, Mackenzie
Wissmueller, Sandra
Campbell, Douglas
Klingemann, Hans
Walsh, Brad
Palapattu, Ganesh S.
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Minom Int Ltd, Macqaurie Pk, Australia
[3] Minom Int Ltd, Sydney, NSW, Australia
[4] NantKwest Inc, Culver City, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
174
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Characterization of Slit protein interactions with glypican-1
    Ronca, F
    Andersen, JS
    Paech, V
    Margolis, RU
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) : 29141 - 29147
  • [32] Differential Expression of Glypican-1 in Ameloblastoma Variants
    Bologna-Molina, Ronell
    Mosqueda-Taylor, Adalberto
    Molina-Frechero, Nelly
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (02) : 153 - 160
  • [33] Involvement of glypican-1 autoprocessing in scrapie infection
    Lofgren, Kajsa
    Cheng, Fang
    Fransson, Lars-Ake
    Bedecs, Katarina
    Mani, Katrin
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2008, 28 (05) : 964 - 972
  • [34] Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells
    Aikawa, Takurna
    Whipple, Chery A.
    Lopez, Martha E.
    Gunn, Jason
    Young, Alison
    Lander, Arthur D.
    Korc, Murray
    JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01): : 89 - 99
  • [35] Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
    Yeh, Mei-Chun
    Tse, Brian W. C.
    Fletcher, Nicholas L.
    Houston, Zachary H.
    Lund, Maria
    Volpert, Marianna
    Stewart, Chelsea
    Sokolowski, Kamil A.
    Jeet, Varinder
    Thurecht, Kristofer J.
    Campbell, Douglas H.
    Walsh, Bradley J.
    Nelson, Colleen C.
    Russell, Pamela J.
    EJNMMI RESEARCH, 2020, 10 (01)
  • [36] Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
    Mei-Chun Yeh
    Brian W. C. Tse
    Nicholas L. Fletcher
    Zachary H. Houston
    Maria Lund
    Marianna Volpert
    Chelsea Stewart
    Kamil A. Sokolowski
    Varinder Jeet
    Kristofer J. Thurecht
    Douglas H. Campbell
    Bradley J. Walsh
    Colleen C. Nelson
    Pamela J. Russell
    EJNMMI Research, 10
  • [37] Antibody-drug conjugate targeting glypican-1 inhibits tumor growth and tumor angiogenesis for glypican-1 positive cholangiocarcinoma.
    Yokota, Keiichiro
    Serada, Satoshi
    Tsujii, Shigehiro
    Murakami, Ichiro
    Hanazaki, Kazuhiro
    Naka, Tetsuji
    CANCER RESEARCH, 2021, 81 (13)
  • [38] A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
    Maria E. Lund
    Christopher B. Howard
    Kristofer J. Thurecht
    Douglas H. Campbell
    Stephen M. Mahler
    Bradley J. Walsh
    BMC Cancer, 20
  • [39] In-vitro validation of Glypican-1 as a novel potential target for antibody- or CAR-based therapies of triple-negative breast cancer (TNBC)
    Mueller, C.
    Lehmann, J.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 364 - 364
  • [40] A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
    Lund, Maria E.
    Howard, Christopher B.
    Thurecht, Kristofer J.
    Campbell, Douglas H.
    Mahler, Stephen M.
    Walsh, Bradley J.
    BMC CANCER, 2020, 20 (01)
12345